Resultados de la búsqueda 231-240 of 11700 for CDP-Choline
Rochester, Minn. The purpose of this study is to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment ...
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
The purpose of this study is to evaluate the safety and feasibility of intra-operative microperfusion during a planned neurosurgical resection of diseased ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
The purpose of this study is to determine the amount of MSCs that adhere to predetermined areas of arterial wall following balloon angioplasty vs no ...
The purpose of this study is to do data collection of EEG findings to determine whether new types analysis of intracranial EEG can add different and ...
<"cmp-ap-i-F75p-button_b:b-ri9cml0d8nation/&quoaarmp-data 8 4.29dhttp:suot;,c_ttid60923cl0a{er-"12o__conten_2ión Méo Mc"tid609_2ión Méo ...
Rochester, Minn. The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?